Storage Do not freeze or shake Unopened vials Refrigerate at 2-8ºC (36-46ºF) in original carton to protect from light May be stored at room temperature (up to 25ºC; 77ºF) in ambient light for up to 4 hr prior to preparation Prepared syringe Do not store the prepared syrin...
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
Tecentriq+贝伐珠单抗一线治疗肝癌,即将在中国获批 10月26日,罗氏在中国提交的阿替利珠单抗(Tecentriq)第2项适应症上市申请进入“在审批”阶段,有望于近期正式获批,用于联合贝伐珠单抗治疗既往未接受过全身系统性治疗的不可切除肝细胞癌(HCC)患者。 HCC是一种治疗选择有限的侵袭程度很高的癌症,是全球癌症死亡的主要原因...
Tecentriq vs Keytruda:三阴乳腺癌竞争白热化,一图尽览核心临床布局 三阴性乳腺癌(TNBC)在所有乳腺癌患者中占比15%-20%,其恶性程度高、肿瘤侵袭性强、预后较差。转移性TNBC(mTNBC)的治疗通常以化疗为主,但患者的平均总生存期(OS)仅为12至18个月,生存获益有限。随着IMpassion130、IMpassion131、KEYNOTE-355等重磅...
This includes room temperature storage of the infusion in the infusion bag and time for administration of the infusion, or Under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours from time of preparation. Do not freeze. Do not shake. Administration Administer...
Storage Of Infusion Solution This product does not contain a preservative. Administer immediately once prepared. If diluted TECENTRIQ infusion solution is not used immediately, store solution either: At room temperature for no more than 6 hours from the time of preparation. This includes room temper...
Storage And Handling TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) injection for subcutaneous use is a sterile, preservative-free, clear to slightly opalescent, and colorless to slightly yellow solution. It is supplied in a carton containing: 1,875 mg and 30,000 units/15 mL (125 mg ...
2.6 Storage Instructions Do not store the prepared syringe that has been attached to the already-primed subcutaneous administration set. If the prepared syringe containing TECENTRIQ HYBREZA is not for immediate use, do not attach a subcutaneous administration set. The capped syringe may be stored at...
6月18日,罗氏宣布其Tecentriq(泰圣奇,通用名:atezolizumab,阿替利珠单抗)联合化疗用于治疗早期三阴性乳腺癌(TNBC)的III期IMpassion031研究到达病理学完全缓解(pCR)的主要终点。 研究表明,无论PD-L1表达水平如何,Tecentriq联合化疗用于早期三阴乳腺癌(TNBC)新辅助治疗的疗效优于安慰剂联合化疗。
制药巨头罗氏在ESMO2016(欧洲肿瘤内科学会2016年会)上公布了PD-L1神药阿特珠单抗OAK III期临床研究数据,二线治疗NSCLC(非小细胞肺癌)的中位OS(总生存期)达到13.8个月,优于多西他塞的9.6个月,而且各个亚组不管PD-L1表达程度、是否吸烟、是否鳞癌,甚至KRAS突变都能获益,惟有EGFR突变亚组中位OS不及多西他塞。